18.08.2016 Protagonist is the fourth company in our portfolio that successfully went public on NASDAQ. Pharmstandard International has participated in the offering. The upsized IPO was completed at $12 per share that represents a solid step-up to previous investment rounds Moscow, Russia, August 11, 2016
– A portfolio company of Pharmstandard International, S.A., Protagonist Therapeutics, Inc. (NASDAQ: PTGX), that is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs, announced on August 10, 2016 the pricing of its initial public offering of 7,500,000 shares of common stock, at a price to the public of $12 per share, before underwriting discounts and commissions. The shares began trading on The NASDAQ Global Market on August 11, 2016, under the symbol «PTGX.» In addition, Protagonist has granted the underwriters a 30-day option to purchase up to 1,125,000 additional shares at the initial public offering price, less underwriting discounts and commissions.
This offering closed on August 16, 2016, subject to customary closing conditions. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on August 10, 2016. About Pharmstandard International S.A. / Inbio Ventures
Pharmstandard International S.A. – is a company with the main focus on venture investments in innovative medicines/therapies with strong potential both globally and in Russia. Pharmstandard International S.A. is a fully owned subsidiary of PJSC Pharmstandard (LSE:PHST) – Russia's leading pharmaceutical producer. For more information, please visit: www.pharmstd.lu
Inbio Ventures JSC – is a management company representing Pharmstandard International S.A., and providing professional support in venture transactions. For more information, please visit: http://www.pharmstd-ventures.com/